On April 7, 2023, Pear Therapeutics Inc. and its wholly owned subsidiary, Pear Therapeutics (US), Inc. (collectively, the “Debtors”) each voluntarily filed for Chapter 11 bankruptcy protection in the United States Bankruptcy Court for the District of Delaware (Case Nos. 23-10429; 23-20430). The Debtors intend to pursue a sale of the business or assets under section 363 of the Bankruptcy Code.
Our hope is that our business and/or products will be purchased so that another company can provide them to patients. Pear Therapeutics is not accepting new prescriptions for its products, reSET®, reSET-O®, and Somryst®, nor will refills be dispensed at this time. We will attempt to keep our products available for patients who are already using the products for the duration of the current fill of their prescription, but there can be no assurance that we will be able to do so.
Additional information about the Company’s Chapter 11 case may be found on both the Company’s website, www.peartherapeutics.com, or the website of the Company’s Bankruptcy Claims and Noticing Agent, Stretto, at https://cases.stretto.com/PearTherapeutics; or by calling Stretto’s hotline at 855.944.1910 (for toll-free U.S. and Canada calls) or 714.252.6860 (for tolled international calls) or via email at TeamPearTherapeutics@stretto.com.
Pear Therapeutics Files for Chapter 11 and Will Seek to Sell Assets Through Sales Process